T-cell activation and transplantation tolerance

Transplantation Reviews

Volumn 26, Issue 3, 2012, Pages 212-222

  Priyadharshini, Bhavana ^a   Greiner, Dale L ^a   Brehm, Michael A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD40 LIGAND; CD70 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ALLORECOGNITION; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CLONAL ANERGY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; INFLAMMATION; LIGAND BINDING; MEMORY T LYMPHOCYTE; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION TOLERANCE; UPREGULATION;

EID: 84863102576     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2011.09.002     Document Type: Review

References (193)

1. Battaglia M. Potential T regulatory cell therapy in transplantation: how far have we come and how far can we go?. Transpl Int 2010, 23:761-770.
2. Ford M.L., Larsen C.P. Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev 2009, 229:294-306.
3. Hale J.S., Fink P.J. Back to the thymus: peripheral T cells come home. Immunol Cell Biol 2009, 87:58-64.
4. Liu E.H., Siegel R.M., Harlan D.M., et al. T cell-directed therapies: lessons learned and future prospects. Nat Immunol 2007, 8:25-30.
5. Liu C., Noorchashm H., Sutter J.A., et al. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med 2007, 13:1295-1298.
6. Markees T.G., Phillips N.E., Gordon E.J., et al. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. J Clin Invest 1998, 101:2446-2455.
7. Markees T.G., Phillips N.E., Noelle R.J., et al. Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand. Transplantation 1997, 64:329-335.
8. Parker D.C., Greiner D.L., Phillips N.E., et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 1995, 92:9560-9564.
9. Alegre M.L., Leemans J., Le Moine A., et al. The multiple facets of Toll-like receptors in transplantation biology. Transplantation 2008, 86:1-9.
10. Miller D.M., Rossini A.A., Greiner D.L. Role of innate immunity in transplantation tolerance. Crit Rev Immunol 2008, 28:403-439.
11. Valujskikh A., Lakkis F.G. In remembrance of things past: memory T cells and transplant rejection. Immunol Rev 2003, 196:65-74.
12. Valujskikh A., Baldwin W.M., Fairchild R.L. Recent progress and new perspectives in studying T-cell responses to allografts. Am J Transplant 2010, 10:1117-1125.
13. Curtsinger J.M., Mescher M.F. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol 2010, 22:333-340.
14. Kaech S.M., Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol 2001, 2:415-422.
15. van Stipdonk M.J., Lemmens E.E., Schoenberger S.P. Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2001, 2:423-429.
16. Wong P., Pamer E.G. Cutting edge: antigen-independent CD8 T cell proliferation. J Immunol 2001, 166:5864-5868.
17. Davis M.M., Chien Y.H., Gascoigne N.R., et al. A murine T cell receptor gene complex: isolation, structure and rearrangement. Immunol Rev 1984, 81:235-258.
18. Braciale T.J., Braciale V.L., Winkler M., et al. On the role of the transmembrane anchor sequence of influenza hemagglutinin in target cell recognition by class I MHC-restricted, hemagglutinin-specific cytolytic T lymphocytes. J Exp Med 1987, 166:678-692.
19. Townsend A.R., Bastin J., Gould K., et al. Cytotoxic T lymphocytes recognize influenza haemagglutinin that lacks a signal sequence. Nature 1986, 324:575-577.
20. Zinkernagel R.M., Doherty P.C. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974, 248:701-702.
21. Zinkernagel R.M., Doherty P.C. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature 1974, 251:547-548.
22. Detours V., Perelson A.S. The paradox of alloreactivity and self MHC restriction: quantitative analysis and statistics. Proc Natl Acad Sci USA 2000, 97:8479-8483.
23. Ford M.L., Koehn B.H., Wagener M.E., et al. Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. J Exp Med 2007, 204:299-309.
24. Heeger P.S. T-cell allorecognition and transplant rejection: a summary and update. Am J Transplant 2003, 3:525-533.
25. Suchin E.J., Langmuir P.B., Palmer E., et al. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001, 166:973-981.
26. Womer K.L., Sayegh M.H., Auchincloss H. Involvement of the direct and indirect pathways of allorecognition in tolerance induction. Philos Trans R Soc Lond, B, Biol Sci 2001, 356:639-647.
27. Lechler R.I., Garden O.A., Turka L.A. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol 2003, 3:147-158.
28. Felix N.J., Donermeyer D.L., Horvath S., et al. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat Immunol 2007, 8:388-397.
29. Reiser J.B., Darnault C., Guimezanes A., et al. Crystal structure of a T cell receptor bound to an allogeneic MHC molecule. Nat Immunol 2000, 1:291-297.
30. Bolton E.M., Bradley J.A., Pettigrew G.J. Indirect allorecognition: not simple but effective. Transplantation 2008, 85:667-669.
31. Valujskikh A., Lantz O., Celli S., et al. Cross-primed CD8(+) T cells mediate graft rejection via a distinct effector pathway. Nat Immunol 2002, 3:844-851.
32. Li X.C., Rothstein D.M., Sayegh M.H. Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev 2009, 229:271-293.
33. Schwartz R.H. A cell culture model for T lymphocyte clonal anergy. Science 1990, 248:1349-1356.
34. Jenkins M.K., Taylor P.S., Norton S.D., et al. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991, 147:2461-2466.
35. Linsley P.S., Brady W., Urnes M., et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991, 174:561-569.
36. Walunas T.L., Lenschow D.J., Bakker C.Y., et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994, 1:405-413.
37. Clarkson M.R., Sayegh M.H. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation 2005, 80:555-563.
38. McAdam A.J., Chang T.T., Lumelsky A.E., et al. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J Immunol 2000, 165:5035-5040.
39. Coyle A.J., Lehar S., Lloyd C., et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 2000, 13:95-105.
40. Sharpe A.H., Freeman G.J. The B7-CD28 superfamily. Nat Rev Immunol 2002, 2:116-126.
41. Latchman Y., Wood C.R., Chernova T., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001, 2:261-268.
42. Freeman G.J., Long A.J., Iwai Y., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192:1027-1034.
43. Rothstein D.M., Sayegh M.H. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev 2003, 196:85-108.
44. Nishimura H., Minato N., Nakano T., et al. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol 1998, 10:1563-1572.
45. Nurieva R.I., Liu X., Dong C. Yin-yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev 2009, 229:88-100.
46. Dong H., Zhu G., Tamada K., et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999, 5:1365-1369.
47. Shin T., Yoshimura K., Crafton E.B., et al. In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med 2005, 201:1531-1541.
48. Subudhi S.K., Zhou P., Yerian L.M., et al. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest 2004, 113:694-700.
49. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?. Nat Rev Immunol 2003, 3:609-620.
50. Quezada S.A., Jarvinen L.Z., Lind E.F., et al. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004, 22:307-328.
51. Larsen C.P., Pearson T.C. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol 1997, 9:641-647.
52. Borst J., Sluyser C., De Vries E., et al. Alternative molecular form of human T cell-specific antigen CD27 expressed upon T cell activation. Eur J Immunol 1989, 19:357-364.
53. Morel Y., Schiano de Colella J.M., Harrop J., et al. Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J Immunol 2000, 165:4397-4404.
54. Tamada K., Shimozaki K., Chapoval A.I., et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med 2000, 6:283-289.
55. Agematsu K., Kobata T., Sugita K., et al. Role of CD27 in T cell immune response. Analysis by recombinant soluble CD27. J Immunol 1994, 153:1421-1429.
56. Hintzen R.Q., Lens S.M., Lammers K., et al. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol 1995, 154:2612-2623.
57. Akiba H., Miyahira Y., Atsuta M., et al. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J Exp Med 2000, 191:375-380.
58. Gramaglia I., Weinberg A.D., Lemon M., et al. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998, 161:6510-6517.
59. Walker L.S., Gulbranson-Judge A., Flynn S., et al. Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers. J Exp Med 1999, 190:1115-1122.
60. Dawicki W., Bertram E.M., Sharpe A.H., et al. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J Immunol 2004, 173:5944-5951.
61. Tan J.T., Whitmire J.K., Ahmed R., et al. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses. J Immunol 1999, 163:4859-4868.
62. Tan J.T., Whitmire J.K., Murali-Krishna K., et al. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination. J Immunol 2000, 164:2320-2325.
63. Dai Z., Li Q., Wang Y., et al. CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism. J Clin Invest 2004, 113:310-317.
64. Dai Z., Nasr I.W., Reel M., et al. Impaired recall of CD8 memory T cells in immunologically privileged tissue. J Immunol 2005, 174:1165-1170.
65. Kurts C., Carbone F.R., Krummel M.F., et al. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 1999, 398:341-344.
66. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005, 23:23-68.
67. Harty J.T., Badovinac V.P. Shaping and reshaping CD8+ T-cell memory. Nat Rev Immunol 2008, 8:107-119.
68. Bevan M.J. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004, 4:595-602.
69. Rocha B., Tanchot C. Towards a cellular definition of CD8+ T-cell memory: the role of CD4+ T-cell help in CD8+ T-cell responses. Curr Opin Immunol 2004, 16:259-263.
70. Bennett S.R., Carbone F.R., Karamalis F., et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998, 393:478-480.
71. Ridge J.P., Di Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998, 393:474-478.
72. Schoenberger S.P., Toes R.E., van der Voort E.I., et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393:480-483.
73. Marzo A.L., Vezys V., Klonowski K.D., et al. Fully functional memory CD8 T cells in the absence of CD4 T cells. J Immunol 2004, 173:969-975.
74. Janssen E.M., Lemmens E.E., Wolfe T., et al. CD4(+) T cells are required for secondary expansion and memory in CD8(+) T lymphocytes. Nature 2003, 421:852-856.
75. Shedlock D.J., Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003, 300:337-339.
76. Peacock C.D., Kim S.K., Welsh R.M. Attrition of virus-specific memory CD8+ T cells during reconstitution of lymphopenic environments. J Immunol 2003, 171:655-663.
77. D'Souza W.N., Lefrançois L. IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J Immunol 2003, 171:5727-5735.
78. Yu A., Zhou J., Marten N., et al. Efficient induction of primary and secondary T cell-dependent immune responses in vivo in the absence of functional IL-2 and IL-15 receptors. J Immunol 2003, 170:236-242.
79. Williams M.A., Tyznik A.J., Bevan M.J. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 2006, 441:890-893.
80. Wilson E.B., Livingstone A.M. Cutting edge: CD4+ T cell-derived IL-2 is essential for help-dependent primary CD8+ T cell responses. J Immunol 2008, 181:7445-7448.
81. Jones N.D., Carvalho-Gaspar M., Luo S., et al. Effector and memory CD8+ T cells can be generated in response to alloantigen independently of CD4+ T cell help. J Immunol 2006, 176:2316-2323.
82. Wu Z., Wang Y., Gao F., et al. Critical role of CD4 help in CD154 blockade-resistant memory CD8 T cell activation and allograft rejection in sensitized recipients. J Immunol 2008, 181:1096-1102.
83. Horne P.H., Koester M.A., Jayashankar K., et al. Disparate primary and secondary allospecific CD8+ T cell cytolytic effector function in the presence or absence of host CD4+ T cells. J Immunol 2007, 179:80-88.
84. Ng Y.H., Oberbarnscheidt M.H., Chandramoorthy H.C., et al. B cells help alloreactive T cells differentiate into memory T cells. Am J Transplant 2010, 10:1970-1980.
85. Curtsinger J.M., Schmidt C.S., Mondino A., et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 1999, 162:3256-3262.
86. Schmidt C.S., Mescher M.F. Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD8+ T cells in vivo. J Immunol 1999, 163:2561-2567.
87. Curtsinger J.M., Valenzuela J.O., Agarwal P., et al. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 2005, 174:4465-4469.
88. Xiao Z., Casey K.A., Jameson S.C., et al. Programming for CD8 T cell memory development requires IL-12 or type I IFN. J Immunol 2009, 182:2786-2794.
89. Aichele P., Unsoeld H., Koschella M., et al. CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion. J Immunol 2006, 176:4525-4529.
90. Curtsinger J.M., Lins D.C., Mescher M.F. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 2003, 197:1141-1151.
91. Kolumam G.A., Thomas S., Thompson L.J., et al. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 2005, 202:637-650.
92. Mitchell T.C., Hildeman D., Kedl R.M., et al. Immunological adjuvants promote activated T cell survival via induction of Bcl-3. Nat Immunol 2001, 2:397-402.
93. Hochrein H., Shortman K., Vremec D., et al. Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets. J Immunol 2001, 166:5448-5455.
94. Mescher M.F., Curtsinger J.M., Agarwal P., et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 2006, 211:81-92.
95. Marshall H.D., Prince A.L., Berg L.J., et al. IFN-alpha beta and self-MHC divert CD8 T cells into a distinct differentiation pathway characterized by rapid acquisition of effector functions. J Immunol 2010, 185:1419-1428.
96. LaRosa D.F., Rahman A.H., Turka L.A. The innate immune system in allograft rejection and tolerance. J Immunol 2007, 178:7503-7509.
97. Goldstein D.R., Tesar B.M., Akira S., et al. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003, 111:1571-1578.
98. Tesar B.M., Zhang J., Li Q., et al. TH1 immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88, a Toll-like receptor signal adaptor protein. Am J Transplant 2004, 4:1429-1439.
99. Oberbarnscheidt M.H., Obhrai J.S., Williams A.L., et al. Type I interferons are not critical for skin allograft rejection or the generation of donor-specific CD8+ memory T cells. Am J Transplant 2010, 10:162-167.
100. Li X.C., Strom T.B., Turka L.A., et al. T cell death and transplantation tolerance. Immunity 2001, 14:407-416.
101. Schwartz R.H. T cell anergy. Annu Rev Immunol 2003, 21:305-334.
102. Turka L.A., Linsley P.S., Lin H., et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992, 89:11102-11105.
103. Lenschow D.J., Walunas T.L., Bluestone J.A. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996, 14:233-258.
104. Salomon B., Bluestone J.A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001, 19:225-252.
105. Tan P., Anasetti C., Hansen J.A., et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993, 177:165-173.
106. Azuma H., Chandraker A., Nadeau K., et al. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci USA 1996, 93:12439-12444.
107. Baliga P., Chavin K.D., Qin L., et al. CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation 1994, 58:1082-1090.
108. Chandraker A., Azuma H., Nadeau K., et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998, 101:2309-2318.
109. Sayegh M.H., Akalin E., Hancock W.W., et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995, 181:1869-1874.
110. Lin H., Bolling S.F., Linsley P.S., et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993, 178:1801-1806.
111. Sayegh M.H., Zheng X.G., Magee C., et al. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients. Transplantation 1997, 64:1646-1650.
112. Kirk A.D., Harlan D.M., Armstrong N.N., et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997, 94:8789-8794.
113. Hancock W.W., Sayegh M.H., Zheng X.G., et al. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci USA 1996, 93:13967-13972.
114. Chen L., Wang T., Zhou P., et al. TLR engagement prevents transplantation tolerance. Am J Transplant 2006, 6:2282-2291.
115. Seung E., Mordes J.P., Rossini A.A., et al. Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning. J Clin Invest 2003, 112:795-808.
116. Elster E.A., Xu H., Tadaki D.K., et al. Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates. Transplantation 2001, 72:1473-1478.
117. Kenyon N.S., Chatzipetrou M., Masetti M., et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci USA 1999, 96:8132-8137.
118. Kenyon N.S., Fernandez L.A., Lehmann R., et al. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 1999, 48:1473-1481.
119. Kirk A.D., Burkly L.C., Batty D.S., et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999, 5:686-693.
120. Inwald D.P., McDowall A., Peters M.J., et al. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003, 92:1041-1048.
121. Kawai T., Andrews D., Colvin R., et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000, 6:114.
122. Adams A.B., Shirasugi N., Jones T.R., et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005, 174:542-550.
123. Aoyagi T., Yamashita K., Suzuki T., et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am J Transplant 2009, 9:1732-1741.
124. Thompson P., Cardona K., Russell M., et al. CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am J Transplant 2011, 11:947-957.
125. Larsen C.P., Elwood E.T., Alexander D.Z., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996, 381:434-438.
126. Williams M.A., Trambley J., Ha J., et al. Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts. J Immunol 2000, 165:6849-6857.
127. Gilson C.R., Milas Z., Gangappa S., et al. Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation. J Immunol 2009, 183:1625-1635.
128. Haanstra K.G., Ringers J., Sick E.A., et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 2003, 75:637-643.
129. Ildstad S.T., Sachs D.H. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984, 307:168-170.
130. Odorico J.S., Posselt A.M., Naji A., et al. Promotion of rat cardiac allograft survival by intrathymic inoculation of donor splenocytes. Transplantation 1993, 55:1104-1107.
131. Jones N.D., Fluck N.C., Mellor A.L., et al. The induction of transplantation tolerance by intrathymic (i.t.) delivery of alloantigen: a critical relationship between i.t. deletion, thymic export of new T cells and the timing of transplantation. Int Immunol 1998, 10:1637-1646.
132. Wekerle T., Blaha P., Koporc Z., et al. Mechanisms of tolerance induction through the transplantation of donor hematopoietic stem cells: central versus peripheral tolerance. Transplantation 2003, 75:21S-25S.
133. Arnold B. Levels of peripheral T cell tolerance. Transpl Immunol 2002, 10:109-114.
134. Iwakoshi N.N., Markees T.G., Turgeon N., et al. Skin allograft maintenance in a new synchimeric model system of tolerance. J Immunol 2001, 167:6623-6630.
135. Wells A.D., Li X.C., Li Y., et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999, 5:1303-1307.
136. Krammer P.H., Arnold R., Lavrik I.N. Life and death in peripheral T cells. Nat Rev Immunol 2007, 7:532-542.
137. Wekerle T., Kurtz J., Sayegh M., et al. Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J Immunol 2001, 166:2311-2316.
138. Bouillet P., O'reilly L.A. CD95, BIM and T cell homeostasis. Nat Rev Immunol 2009, 9:514-519.
139. Li X.C., Wells A.D., Strom T.B., et al. The role of T cell apoptosis in transplantation tolerance. Curr Opin Immunol 2000, 12:522-527.
140. Kurtz J., Lie A., Griffith M., et al. Lack of role for CsA-sensitive or Fas pathways in the tolerization of CD4 T cells via BMT and anti-CD40L. Am J Transplant 2003, 3:804-816.
141. Brehm M.A., Mangada J., Markees T.G., et al. Rapid quantification of naive alloreactive T cells by TNF-alpha production and correlation with allograft rejection in mice. Blood 2007, 109:819-826.
142. Thornley T.B., Brehm M.A., Markees T.G., et al. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J Immunol 2006, 176:1561-1570.
143. Schwartz R.H. Models of T cell anergy: is there a common molecular mechanism?. J Exp Med 1996, 184:1-8.
144. Li L., Boussiotis V.A. Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications. J Mol Med 2006, 84:887-899.
145. Dallman M.J., Shiho O., Page T.H., et al. Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med 1991, 173:79-87.
146. Jones L.A., Chin L.T., Merriam G.R., et al. Failure of clonal deletion in neonatally thymectomized mice: tolerance is preserved through clonal anergy. J Exp Med 1990, 172:1277-1285.
147. Vendetti S., Chai J.G., Dyson J., et al. Anergic T cells inhibit the antigen-presenting function of dendritic cells. J Immunol 2000, 165:1175-1181.
148. Banuelos S.J., Markees T.G., Phillips N.E., et al. Regulation of skin and islet allograft survival in mice treated with costimulation blockade is mediated by different CD4+ cell subsets and different mechanisms. Transplantation 2004, 78:660-667.
149. Wood K.J., Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003, 3:199-210.
150. Sakaguchi S., Sakaguchi N., Asano M., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
151. Wing K., Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010, 11:7-13.
152. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
153. Taylor P.A., Noelle R.J., Blazar B.R. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001, 193:1311-1318.
154. Gregori S., Casorati M., Amuchastegui S., et al. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001, 167:1945-1953.
155. Bestard O., Cruzado J.M., Rama I., et al. Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol 2008, 19:2020-2026.
156. Demirkiran A., Kok A., Kwekkeboom J., et al. Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transpl 2006, 12:277-284.
157. Meloni F., Cascina A., Paschetto E., et al. Monocyte chemoattractant protein-1 levels in bronchoalveolar lavage fluid of lung-transplanted patients treated with tacrolimus as rescue treatment for refractory acute rejection. Transplant Proc 2003, 35:1523-1526.
158. Pons J.A., Revilla-Nuin B., Baroja-Mazo A., et al. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation 2008, 86:1370-1378.
159. Salama A.D., Najafian N., Clarkson M.R., et al. Regulatory CD25+ T cells in human kidney transplant recipients. J Am Soc Nephrol 2003, 14:1643-1651.
160. Issa F., Hester J., Goto R., et al. Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation 2010, 90:1321-1327.
161. Nadig S.N., Wieckiewicz J., Wu D.C., et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010, 16:809-813.
162. Welsh R.M., Markees T.G., Woda B.A., et al. Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. J Virol 2000, 74:2210-2218.
163. Turgeon N., Iwakoshi N., Meyers W., et al. Virus infection abrogates CD8(+) t cell deletion induced by donor-specific transfusion and anti-cd154 monoclonal antibody. Curr Surg 2000, 57:505-506.
164. Williams M.A., Onami T.M., Adams A.B., et al. Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen. J Immunol 2002, 169:5387-5391.
165. Williams M.A., Tan J.T., Adams A.B., et al. Characterization of virus-mediated inhibition of mixed chimerism and allospecific tolerance. J Immunol 2001, 167:4987-4995.
166. Forman D., Welsh R.M., Markees T.G., et al. Viral abrogation of stem cell transplantation tolerance causes graft rejection and host death by different mechanisms. J Immunol 2002, 168:6047-6056.
167. Cook C.H., Bickerstaff A.A., Wang J.J., et al. Disruption of murine cardiac allograft acceptance by latent cytomegalovirus. Am J Transplant 2009, 9:42-53.
168. Ahmed E.B., Daniels M., Alegre M.L., et al. Bacterial infections, alloimmunity, and transplantation tolerance. Transplant Rev (Orlando) 2011, 25:27-35.
169. Pantenburg B., Heinzel F., Das L., et al. T cells primed by Leishmania major infection cross-react with alloantigens and alter the course of allograft rejection. J Immunol 2002, 169:3686-3693.
170. Wang T., Ahmed E.B., Chen L., et al. Infection with the intracellular bacterium, Listeria monocytogenes, overrides established tolerance in a mouse cardiac allograft model. Am J Transplant 2010, 10:1524-1533.
171. Wang T., Chen L., Ahmed E., et al. Prevention of allograft tolerance by bacterial infection with Listeria monocytogenes. J Immunol 2008, 180:5991-5999.
172. Adams A.B., Williams M.A., Jones T.R., et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003, 111:1887-1895.
173. Brehm M.A., Daniels K.A., Priyadharshini B., et al. Allografts stimulate cross-reactive virus-specific memory CD8 T cells with private specificity. Am J Transplant 2010, 10:1738-1748.
174. Brehm M.A., Markees T.G., Daniels K.A., et al. Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections. J Immunol 2003, 170:4077-4086.
175. Brehm M.A., Selin L.K., Welsh R.M. CD8 T cell responses to viral infections in sequence. Cell Microbiol 2004, 6:411-421.
176. Yang H.Y., Dundon P.L., Nahill S.R., et al. Virus-induced polyclonal cytotoxic T lymphocyte stimulation. J Immunol 1989, 142:1710-1718.
177. Burrows S.R., Silins S.L., Khanna R., et al. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. Eur J Immunol 1997, 27:1726-1736.
178. Gamadia L.E., Remmerswaal E.B., Surachno S., et al. Cross-reactivity of cytomegalovirus-specific CD8+ T cells to allo-major histocompatibility complex class I molecules. Transplantation 2004, 77:1879-1885.
179. Landais E., Morice A., Long H.M., et al. EBV-specific CD4+ T cell clones exhibit vigorous allogeneic responses. J Immunol 2006, 177:1427-1433.
180. Selin L.K., Brehm M.A. Frontiers in nephrology: heterologous immunity, T cell cross-reactivity, and alloreactivity. J Am Soc Nephrol 2007, 18:2268-2277.
181. Miller D.M., Thornley T., Pearson T., et al. TLR agonists abrogate co-stimulation blockade-induced mixed chimerism and transplantation tolerance. Ann N Y Acad Sci 2008, 1150:149-151.
182. Brehm M.A., Daniels K.A., Ortaldo J.R., et al. Rapid conversion of effector mechanisms from NK to T cells during virus-induced lysis of allogeneic implants in vivo. J Immunol 2005, 174:6663-6671.
183. Miller D.M., Thornley T.B., Pearson T., et al. TLR agonists prevent the establishment of allogeneic hematopoietic chimerism in mice treated with costimulation blockade. J Immunol 2009, 182:5547-5559.
184. Thornley T.B., Phillips N.E., Beaudette-Zlatanova B.C., et al. Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance. J Immunol 2007, 179:6620-6629.
185. Porrett P.M., Yuan X., LaRosa D.F., et al. Mechanisms underlying blockade of allograft acceptance by TLR ligands. J Immunol 2008, 181:1692-1699.
186. Chen L., Ahmed E., Wang T., et al. TLR signals promote IL-6/IL-17-dependent transplant rejection. J Immunol 2009, 182:6217-6225.
187. Pearson T.C., Alexander D.Z., Winn K.J., et al. Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994, 57:1701-1706.
188. Kirk A.D., Tadaki D.K., Celniker A., et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 2001, 72:377-384.
189. Birsan T., Hausen B., Higgins J.P., et al. Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys. Transplantation 2003, 75:2106-2113.
190. Haspot F., Seveno C., Dugast A.S., et al. Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells. Am J Transplant 2005, 5:2339-2348.
191. Laskowski I.A., Pratschke J., Wilhelm M.J., et al. Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats. J Am Soc Nephrol 2002, 13:519-527.
192. Buhler L., Deng S., O'Neil J., et al. Adult porcine islet transplantation in baboons treated with conventional immunosuppression or a non-myeloablative regimen and CD154 blockade. Xenotransplantation 2002, 9:3-13.
193. Appel M.C., Banuelos S.J., Greiner D.L., et al. Prolonged survival of neonatal porcine islet xenografts in mice treated with a donor-specific transfusion and anti-CD154 antibody. Transplantation 2004, 77:1341-1349.